our vision

Improve the lives of patients and families suffering from rare muscle disorders by building the world’s leading muscle-focused, precision medicine company.

latest news

Edgewise Therapeutics Announces Positive Topline Results From the EDG-5506 Phase 1b Clinical Trial in Adults With Becker Muscular Dystrophy (BMD)

Jan 5, 2022
READ MORE

Edgewise Therapeutics to Report Phase 1b Topline Results of EDG-5506 in Individuals with Becker Muscular Dystrophy (BMD) on January 5, 2022, and Initiates ARCH Follow-On Open Label BMD Study

Dec 15, 2021
READ MORE

Edgewise Therapeutics to Participate at Evercore ISI 4th Annual HEALTHCONx Conference on December 2

Nov 17, 2021
READ MORE

learn about our pipeline

view pipeline